RC
BIIB icon

Rovin Capital’s Biogen BIIB Stock Holding History

Rovin Capital’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,741
Closed -$635K – 171
2024
Q2 		$635K Buy
2,741
+361
+15% +$78.5K 0.26% 76
2024
Q1 		$513K Buy
2,380
+318
+15% +$74.5K 0.21% 93
2023
Q4 		$534K Buy
2,062
+480
+30% +$118K 0.24% 79
2023
Q3 		$407K Sell
1,582
-165
-9% -$44.1K 0.19% 80
2023
Q2 		$498K Sell
1,747
-149
-8% -$44.4K 0.22% 72
2023
Q1 		$527K Sell
1,896
-537
-22% -$149K 0.25% 63
2022
Q4 		$674K Sell
2,433
-145
-6% -$41K 0.34% 52
2022
Q3 		$688K Sell
2,578
-53
-2% -$11.3K 0.39% 43
2022
Q2 		$537K Buy
2,631
+81
+3% +$16.6K 0.36% 54
2022
Q1 		$537K Buy
2,550
+819
+47% +$178K 0.29% 59
2021
Q4 		$415K Buy
+1,731
New +$445K 0.2% 81

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Rovin Capital's BIIB Position: Q3 2024 in Review

Rovin Capital sold out of Biogen (BIIB) in Q3 2024, closing a stake of 2,741 shares — an estimated $635K sold.

Rovin Capital first reported a position in BIIB in Q4 2021 and held it in 11 quarters. The position peaked at $688K in Q3 2022. 917 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

  • Rovin Capital reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
  • Rovin Capital sold 2,741 Biogen shares in Q3 2024, an estimated $635K.
  • Rovin Capital first reported a position in Biogen in Q4 2021 and held it in 11 quarters.
  • Rovin Capital's Biogen position peaked at $688K in Q3 2022.
  • 917 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on Rovin Capital's 13F filing for Q3 2024, filed 1 Nov 2024.